Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.50 |
| ▸ | NMT2 | O60551 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20375383 | 0.88 | GLP1R (0.52) | GLP1RNMT2NMT1MEN1KMT2A | |
| SCHEMBL26634412 | 0.88 | GLP1R (0.51) | GLP1RNMT2NMT1MEN1KMT2A | |
| SCHEMBL26740062 | 0.88 | GLP1R (0.51) | GLP1RNMT2NMT1MEN1KMT2A | |
| SCHEMBL16349899 | 0.87 | ALDH1A1 (0.47) | GLP1RMEN1KMT2ACNR1CNR2 | |
| SCHEMBL19431099 | 0.86 | MEN1 (0.47) | GLP1RMEN1KMT2ACNR1CNR2 | |
| SCHEMBL25555033 | 0.86 | GLP1R (0.47) | GLP1RNMT2NMT1MEN1KMT2A | |
| SCHEMBL26749631 | 0.82 | GLP1R (0.56) | GLP1RMEN1KMT2A | |
| SCHEMBL26748589 | 0.82 | GLP1R (0.56) | GLP1RMEN1KMT2A | |
| SCHEMBL22566705 | 0.81 | GLP1R (0.46) | GLP1RNMT2NMT1MEN1KMT2A | |
| SCHEMBL13616087 | 0.80 | MEN1 (0.53) | GLP1RMEN1KMT2ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200332297-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200332297-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, EIF2AK2 | GLP1R 4386/4885NMT2 2486/4885NMT1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.